Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for APGE

Stock NameApogee Therapeutics, Inc. Common Stock
TickerAPGE(USD) NASDAQ
TYPECommon Stock
CountryUSA

Show aggregate APGE holdings

News associated with APGE

Analysts Set Apogee Therapeutics Inc. (NASDAQ:APGE) PT at $97.29
Apogee Therapeutics Inc. (NASDAQ:APGE – Get Free Report) has received an average rating of “Moderate Buy” from the eight brokerages that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month target price among analysts […] - 2025-09-02 03:06:53
XTX Topco Ltd Raises Stock Holdings in Apogee Therapeutics Inc. (NASDAQ:APGE)
XTX Topco Ltd raised its position in Apogee Therapeutics Inc. (NASDAQ:APGE – Free Report) by 170.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,188 shares of the company’s stock after buying an additional 10,840 shares during the quarter. […] - 2025-08-06 05:16:59
Apogee Therapeutics Inc. (NASDAQ:APGE) Receives $99.00 Average Price Target from Brokerages
Apogee Therapeutics Inc. (NASDAQ:APGE – Get Free Report) has been assigned an average recommendation of “Buy” from the six analysts that are currently covering the company, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have covered the stock in the last year […] - 2025-07-14 02:22:47
Apogee Therapeutics Sees Unusually High Options Volume (NASDAQ:APGE)
Apogee Therapeutics Inc. (NASDAQ:APGE – Get Free Report) saw unusually large options trading activity on Monday. Traders acquired 3,810 put options on the company. This represents an increase of 728% compared to the average daily volume of 460 put options. Insiders Place Their Bets In related news, insider Carl Dambkowski sold 10,090 shares of the […] - 2025-07-09 02:50:45
Financial Review: Apogee Therapeutics (NASDAQ:APGE) vs. argenx (NASDAQ:ARGX)
argenx (NASDAQ:ARGX – Get Free Report) and Apogee Therapeutics (NASDAQ:APGE – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk. Profitability This table compares argenx and Apogee Therapeutics’ net […] - 2025-06-17 02:49:06
Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives Average Rating of “Buy” from Brokerages
Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) has earned an average rating of “Buy” from the five brokerages that are currently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have covered the stock in the last year is […] - 2025-06-16 04:11:05
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Acquired by Squarepoint Ops LLC
Squarepoint Ops LLC raised its holdings in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) by 90.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 36,344 shares of the company’s stock after acquiring an additional 17,301 shares during the […] - 2025-05-30 05:34:59
Millennium Management LLC Has $5.90 Million Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)
Millennium Management LLC boosted its position in Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) by 44.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 130,171 shares of the company’s stock after purchasing an additional 40,162 shares during the period. Millennium Management LLC’s holdings in Apogee Therapeutics were […] - 2025-05-28 04:56:52
Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives $94.60 Consensus PT from Analysts
Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) have received an average rating of “Buy” from the five ratings firms that are covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have issued ratings on the stock in […] - 2025-05-27 05:56:59
ProShare Advisors LLC Increases Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)
ProShare Advisors LLC grew its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) by 30.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,805 shares of the company’s stock after purchasing an additional 2,985 shares […] - 2025-05-26 05:18:49
We Did The Math SMLF Can Go To $77
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-06 08:38:07
Analyzing Apogee Therapeutics (NASDAQ:APGE) and Zura Bio (NASDAQ:ZURA)
Zura Bio (NASDAQ:ZURA – Get Free Report) and Apogee Therapeutics (NASDAQ:APGE – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership. Profitability This table compares Zura Bio and […] - 2025-05-06 02:30:46
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Target Price at $92.17
Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) has earned an average recommendation of “Buy” from the six analysts that are covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have updated their coverage on the stock in the […] - 2025-04-21 02:14:46
KLP Kapitalforvaltning AS Acquires Shares of 5,000 Apogee Therapeutics, Inc. (NASDAQ:APGE)
KLP Kapitalforvaltning AS bought a new position in Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 5,000 shares of the company’s stock, valued at approximately $226,000. Other large investors have also recently made changes to their […] - 2025-04-08 04:32:50
Apogee Therapeutics, Inc. (NASDAQ:APGE) Position Reduced by Bank of New York Mellon Corp
Bank of New York Mellon Corp lowered its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) by 1.6% in the 4th quarter, Holdings Channel.com reports. The firm owned 110,827 shares of the company’s stock after selling 1,774 shares during the period. Bank of New York Mellon Corp’s holdings in Apogee Therapeutics were worth $5,020,000 […] - 2025-03-18 05:09:01
Apogee Therapeutics (NASDAQ:APGE) Now Covered by Citigroup
Citigroup began coverage on shares of Apogee Therapeutics (NASDAQ:APGE – Free Report) in a research note released on Thursday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $95.00 target price on the stock. A number of other brokerages have also recently issued reports on APGE. Canaccord Genuity Group assumed coverage on Apogee […] - 2025-03-14 05:48:55
Apogee Therapeutics (NASDAQ:APGE) Earns Outperform Rating from Wedbush
Wedbush reaffirmed their outperform rating on shares of Apogee Therapeutics (NASDAQ:APGE – Free Report) in a research note issued to investors on Tuesday morning,RTT News reports. The firm currently has a $90.00 price objective on the stock. Other equities research analysts have also recently issued research reports about the stock. Canaccord Genuity Group assumed coverage […] - 2025-03-12 04:56:50
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by Handelsbanken Fonder AB
Handelsbanken Fonder AB trimmed its holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) by 14.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 7,500 shares of the company’s stock after selling 1,300 shares during the period. Handelsbanken Fonder AB’s holdings […] - 2025-03-04 06:46:55
Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives Consensus Recommendation of “Buy” from Brokerages
Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) have been given a consensus rating of “Buy” by the seven research firms that are presently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued ratings on […] - 2025-03-04 04:47:02
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) PT at $89.71
Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) have been given an average rating of “Buy” by the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have covered the stock […] - 2025-02-05 04:06:46

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) APGE holdings

DateNumber of APGE Shares HeldBase Market Value of APGE SharesLocal Market Value of APGE SharesChange in APGE Shares HeldChange in APGE Base ValueCurrent Price per APGE Share HeldPrevious Price per APGE Share Held
2025-11-11 (Tuesday)29,584USD 1,862,313USD 1,862,313
2025-11-10 (Monday)29,584APGE holding increased by 76USD 1,679,484APGE holding increased by 65101USD 1,679,48476USD 65,101 USD 56.77 USD 54.71
2025-11-07 (Friday)29,508USD 1,614,383APGE holding decreased by -8409USD 1,614,3830USD -8,409 USD 54.71 USD 54.995
2025-11-06 (Thursday)29,508APGE holding increased by 76USD 1,622,792APGE holding decreased by -9212USD 1,622,79276USD -9,212 USD 54.995 USD 55.45
2025-11-05 (Wednesday)29,432USD 1,632,004APGE holding increased by 45619USD 1,632,0040USD 45,619 USD 55.45 USD 53.9
2025-11-04 (Tuesday)29,432APGE holding increased by 76USD 1,586,385APGE holding decreased by -9114USD 1,586,38576USD -9,114 USD 53.9 USD 54.35
2025-11-03 (Monday)29,356USD 1,595,499APGE holding decreased by -65757USD 1,595,4990USD -65,757 USD 54.35 USD 56.59
2025-10-31 (Friday)29,356USD 1,661,256APGE holding increased by 16146USD 1,661,2560USD 16,146 USD 56.59 USD 56.04
2025-10-30 (Thursday)29,356APGE holding increased by 380USD 1,645,110APGE holding increased by 31147USD 1,645,110380USD 31,147 USD 56.04 USD 55.7
2025-10-29 (Wednesday)28,976APGE holding increased by 152USD 1,613,963APGE holding decreased by -11134USD 1,613,963152USD -11,134 USD 55.7 USD 56.38
2025-10-28 (Tuesday)28,824USD 1,625,097APGE holding increased by 4323USD 1,625,0970USD 4,323 USD 56.38 USD 56.23
2025-10-27 (Monday)28,824USD 1,620,774APGE holding increased by 83878USD 1,620,7740USD 83,878 USD 56.23 USD 53.32
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of APGE by Blackrock for IE00BYXG2H39

Show aggregate share trades of APGE

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY7657.53055.585 55.779USD 4,239 41.63
2025-11-06BUY7656.00053.630 53.867USD 4,094 41.49
2025-11-04BUY7654.71053.010 53.180USD 4,042 41.36
2025-10-30BUY38057.00055.350 55.515USD 21,096 41.13
2025-10-29BUY15255.70056.782 56.674USD 8,614 41.06
2025-10-22SELL-30453.48055.850 55.613USD -16,906 40.69 Loss of -4,536 on sale
2025-10-20BUY15256.94057.030 57.021USD 8,667 40.52
2025-10-17BUY38055.15055.580 55.537USD 21,104 40.44
2025-10-15BUY60855.85056.225 56.187USD 34,162 40.35
2025-10-03BUY53239.88040.420 40.366USD 21,475 40.29
2025-10-02BUY7639.61039.850 39.826USD 3,027 40.29
2025-09-30BUY15239.73040.200 40.153USD 6,103 40.30
2025-09-26BUY15238.22038.250 38.247USD 5,814 40.32
2025-09-25BUY15237.52038.800 38.672USD 5,878 40.33
2025-09-24SELL-1,00938.42038.600 38.582USD -38,929 40.34 Profit of 1,777 on sale
2025-09-18BUY7938.43038.880 38.835USD 3,068 40.35
2025-09-17BUY23737.63039.145 38.994USD 9,241 40.37
2025-08-20SELL-31636.02036.680 36.614USD -11,570 40.47 Profit of 1,217 on sale
2025-07-30BUY31637.61038.310 38.240USD 12,084 40.58
2025-07-17SELL-15839.00039.320 39.288USD -6,208 40.63 Profit of 212 on sale
2025-07-11SELL-63238.14038.950 38.869USD -24,565 40.70 Profit of 1,156 on sale
2025-07-07BUY23739.24047.485 46.661USD 11,059 40.78
2025-07-02BUY4,34544.32046.670 46.435USD 201,760 40.71
2025-06-20BUY90541.96042.663 42.593USD 38,546 40.70
2025-06-11BUY15242.44043.910 43.763USD 6,652 40.62
2025-06-10BUY15242.02042.150 42.137USD 6,405 40.61
2025-06-04SELL-7636.50038.570 38.363USD -2,916 40.66 Profit of 175 on sale
2025-04-23BUY7636.53038.750 38.528USD 2,928 41.37
2025-04-10SELL-60829.94030.760 30.678USD -18,652 42.24 Profit of 7,030 on sale
2025-04-08SELL-7628.79034.380 33.821USD -2,570 42.52 Profit of 661 on sale
2025-04-07SELL-7632.30032.760 32.714USD -2,486 42.63 Profit of 754 on sale
2025-04-04SELL-38032.32033.660 33.526USD -12,740 42.76 Profit of 3,507 on sale
2025-04-01BUY92035.61037.870 37.644USD 34,632 42.90
2025-03-31SELL-22237.36038.945 38.786USD -8,611 42.97 Profit of 928 on sale
2025-03-21BUY96539.84040.640 40.560USD 39,140 43.21
2025-03-14SELL-1,13639.94041.000 40.894USD -46,456 43.43 Profit of 2,886 on sale
2025-03-07SELL-14236.14037.300 37.184USD -5,280 43.83 Profit of 944 on sale
2025-03-04SELL-7130.37031.320 31.225USD -2,217 44.38 Profit of 934 on sale
2025-02-25BUY14233.06033.855 33.775USD 4,796 45.49
2025-02-19SELL-7133.92035.186 35.059USD -2,489 46.34 Profit of 801 on sale
2025-02-13BUY21336.26036.620 36.584USD 7,792 47.16
2025-02-12BUY7135.50035.590 35.581USD 2,526 47.40
2025-02-11BUY28434.49039.195 38.724USD 10,998 47.67
2024-12-30SELL-2,46844.64046.320 46.152USD -113,903 50.56 Profit of 10,883 on sale
2024-11-18SELL-1,15545.33048.365 48.062USD -55,511 55.25 Profit of 8,300 on sale
2024-11-08SELL-7761.12062.230 62.119USD -4,783 54.68 Loss of -573 on sale
2024-10-21SELL-7752.97053.300 53.267USD -4,102 0.00 Loss of -4,102 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of APGE

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-1970,6630123,32357.3%
2025-09-1855,2200144,94238.1%
2025-09-1757,7220155,74637.1%
2025-09-1643,15180105,79040.8%
2025-09-1581,96129130,78662.7%
2025-09-1271,0510214,65033.1%
2025-09-1194,7640386,86724.5%
2025-09-1059,8630142,02842.1%
2025-09-09111,612257182,11561.3%
2025-09-0897,0380179,71054.0%
2025-09-0569,6230171,26240.7%
2025-09-0453,120232144,34436.8%
2025-09-0374,1230144,59351.3%
2025-09-0266,5154129,84551.2%
2025-08-29101,9740154,87165.8%
2025-08-2859,362161162,55236.5%
2025-08-2767,694500137,14849.4%
2025-08-2656,46712108,27152.2%
2025-08-2558,196079,23373.4%
2025-08-22156,8240213,08373.6%
2025-08-21109,2100159,43368.5%
2025-08-2069,7200118,47158.8%
2025-08-19101,7931,831140,03472.7%
2025-08-1864,930092,96969.8%
2025-08-15168,3473,071233,00872.2%
2025-08-1479,489519209,64137.9%
2025-08-13137,5100206,60666.6%
2025-08-1298,0690228,50942.9%
2025-08-11128,020262163,34878.4%
2025-08-08158,4020252,33962.8%
2025-08-0796,25430146,85265.5%
2025-08-06183,75215346,21353.1%
2025-08-05113,13150216,68452.2%
2025-08-0486,0420161,95853.1%
2025-08-01164,1571,952329,21949.9%
2025-07-31116,4000253,05946.0%
2025-07-30120,1010257,28646.7%
2025-07-29131,8820256,50551.4%
2025-07-28147,442296276,56853.3%
2025-07-25113,9740225,87150.5%
2025-07-24124,1445236,30452.5%
2025-07-2385,8770205,61841.8%
2025-07-2297,6130213,62145.7%
2025-07-21183,75260441,69041.6%
2025-07-18119,198324364,43532.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.